SUMMARY B cell activation during normal immune responses and oncogenic transformation impose increased metabolic demands on B cells and their ability to retain redox homeostasis. While the serine/threonine-protein phosphatase 2A (PP2A) was identified as a tumor suppressor in multiple types of cancer, our genetic studies revealed an essential role of PP2A in B cell tumors. Thereby, PP2A redirects glucose carbon utilization from glycolysis to the pentose phosphate pathway (PPP) to salvage oxidative stress. This unique vulnerability reflects constitutively low PPP activity in B cells and transcriptional repression of G6PD and other key PPP enzymes by the B cell transcription factors PAX5 and IKZF1. Reflecting B-cell-specific transcriptional PPP-repression, glucose carbon utilization in B cells is heavily skewed in favor of glycolysis resulting in lack of PPP-dependent antioxidant protection. These findings reveal a gatekeeper function of the PPP in a broad range of B cell malignancies that can be efficiently targeted by small molecule inhibition of PP2A and G6PD.
In Brief PP2A redirects glucose carbon utilization from glycolysis to the pentose phosphate pathway to salvage oxidative stress in B cell tumors.
INTRODUCTION
The paradigm of targeted therapy of cancer is based on kinase inhibitors, e.g., the prototypic tyrosine kinase inhibitor (TKI) imatinib for the treatment of BCR-ABL1-driven (Ph + ) leukemias (Hochhaus et al., 2017) . Oncogenic signaling frequently involves aberrant activation of kinases, leading to the notion that phosphatases opposing oncogenic kinase signaling have tumor suppressive activity. For instance, the PTEN (Li et al., 1997) and Lakhanpal et al., 2010) phosphatases are classical tumor suppressors and frequently mutated across multiple types of cancer (http://cancer.sanger.ac.uk/cosmic). Likewise, multiple subunits of the serine-threonine-protein phosphatase 2A (PP2A) are recurrently deleted or mutated in a wide range of cancer subtypes (Wang et al., 1998) , demonstrating that PP2A, like PTEN and INPP5D, represents a tumor suppressor. Recent studies from our group revealed that B cell-derived leukemias are uniquely dependent on PTEN and INPP5D function. Inducible deletion of Pten (Shojaee et al., 2016) and Inpp5d phosphatases in B-lineage leukemia cells caused hyperactivation of B cell receptor (BCR)-related tyrosine kinases, which mimics overwhelming signaling strength from an autoreactive BCR (Mü schen 2018). Despite malignant transformation, B-lymphoid leukemia cells fully retain their sensitivity to negative selection and cell death at autoimmunity checkpoints. Interestingly, besides PTEN and INPP5D, also PP2A functions as a critical regulator of negative selection and autoimmunity (Apostolidis et al., 2016; Sharabi et al., 2017) . Because of its role in cancer and autoimmunity, we studied here the function of PP2A in normal B cells and B cell malignancies.
RESULTS AND DISCUSSION
B-Cell-Lineage-Specific Effects of PP2A Ablation PP2A functions as a dimeric holoenzyme composed of a scaffolding subunit A and a catalytic subunit C, which often associates with the regulatory subunit B. As a model for loss of PP2A holoenzyme activity, we studied genetic ablation of the Ppp2r1a gene encoding the PP2A scaffold subunit Aa (PP2A Sub A), which is essential for PP2A activity (Ruediger et al., 2011) .
To test the function of PP2A in normal B cell development and B-lymphoid leukemia and lymphoma, we crossed mice carrying floxed Ppp2r1a alleles (Ruediger et al., 2011) Figure S1A ). Heterozygous Ppp2r1a +/fl Mb1-Cre mice were phenotypically normal and studied as normal control. Phenotypic analyses of bone marrow and splenic B cell populations revealed normal pro-B (fraction B) and early pre-B cell (fraction C) numbers in Ppp2r1a fl/fl Mb1-Cre mice. However, B cell populations were diminished by >10-fold once they reached pre-B cell receptor (pre-BCR)-dependent stages of development (fraction C 0 ; Figures 1A and 1B). Mature splenic B cells were barely detectable upon deletion of Ppp2r1a and numbers were reduced by >20-fold, suggesting that PP2A is also required for survival of mature B cells ( Figure 1C ). These results indicate a stage-specific function of PP2A throughout pre-BCR-and BCR-dependent stages of B cell development. Detailed flow cytometry analyses revealed that ablation of Ppp2r1a resulted in selective loss of pre-BCR-dependent (m-heavy chain) and BCR-dependent (IgM, IgD, Igk) B cell populations ( Figure 1D ). Cre-mediated deletion of Ppp2r1a not only abrogated expression of the PP2A scaffold Sub A but also destabilized protein expression of catalytic Sub C ( Figure 1E ) (Chen et al., 2005) . Conversely, retroviral expression of Sub A rescued normal expression levels of both Sub A and Sub C despite Cre-mediated deletion of Ppp2r1a. While Cre-mediated deletion of Ppp2r1a reduced enzymatic PP2A activity to background levels, retroviral expression of Sub A increased PP2A enzymatic activity by 7-fold (Figures 1F and 1G) . Inducible ablation of Ppp2r1a under cell culture conditions resulted in acute cell death of both pre-BCR + early and BCR + mature B cells ( Figure 1H ). Interestingly, inducible activation of Cre in Ppp2r1a fl/fl myeloid progenitor cells from the same mice had no deleterious effect and slightly increased survival and proliferation, suggesting that dependency on PP2A function is B cell-specific ( Figure 1H ). To directly validate that PP2A regulates cell survival in a strict B cell lineage-dependent manner, Ppp2r1a fl/fl B cell acute lymphoblastic leukemia (ALL) cells were reprogrammed into the myeloid lineage by inducible overexpression of the myeloid transcription factor C/EBPa ( Figure 1I ) (Xie et al., 2004) . While deletion of Ppp2r1a in CD19 + B-ALL cells caused acute cell death, viability of CD11b + C/EBPa-reprogrammed myeloid leukemia cells remained unchanged ( Figure 1I ).
B-ALL Cell Survival Requires PP2A Activity Inducible ablation of Ppp2r1a induced rapid depletion of both BCR-ABL1 and NRAS G12D driven B-ALL cells (Figures S1B and S1C) and suppressed colony forming ability by >10-fold (Figures 2A and 2B) . Conversely, overexpression of Sub A increased competitive fitness and induced outgrowth of Sub A-overexpressing cells ( Figure 2C ). Likewise, Sub A-overexpression quadrupled the number of colonies formed after plating in semisolid methylcellulose ( Figure 2C ). Loss of colony formation capacity upon Ppp2r1a deletion is consistent with DNA-damage (H2AX-phosphorylation) and activation of Arf and p53 (Figures 2D and 2E) . Ablation of Ppp2r1a increased cell death but only slightly affected the cell cycle of B-ALL cells . Mirroring the apoptotic phenotype of B-ALL cells upon Ppp2r1a deletion, upregulation of p53 was paralleled by downregulation of Bcl2 ( Figure 2D ). Taken together, these genetic in vitro studies show that PP2A activity is critical for the survival of B-ALL cells.
Functional Consequences of PP2A Deletion in B-ALL Cells
To study the mechanistic basis of the unexpected dependency of B-ALL cells on PP2A enzymatic activity, we determined the biochemical consequences of Ppp2r1a-deletion. Measurement of changes of the phosphorylation status of signaling molecules in a phospho-protein array revealed moderately increased phosphorylation of Erk and Akt in response to Ppp2r1a-deletion ( Figure S2A ). Increased activation of PI3K and AKT-mTOR may indeed contribute to toxicity upon deletion of Ppp2r1a, because inhibition of PI3K (Idelalisib) and mTOR (Rapamycin) signaling partially rescued cell death in response to Ppp2r1a-deletion ( Figures S2B-S2D ). Downstream of AKT, deletion of Ppp2r1a not only increased activation of mTOR-S6 kinase signaling but also massive phosphorylation and inactivation of FoxO1 and FoxO3a ( Figure S3A ), which are important mediators of redox equilibrium (Nemoto and Finkel, 2002) . To elucidate the significance of FoxO1-and FoxO3a-phosphorylation and inactivation, we determined the effects of inducible Foxo1-deletion in B cell ALL cells. FoxO factors negatively regulate B cell proliferation and are inactivated by AKT-mediated phosphorylation (Yusuf et al., 2004) . However, tamoxifen-inducible deletion of Foxo1 in B-ALL cells abrogated colony formation and caused acute cell Figure 2F ). Gene set enrichment analyses showed a global reduction of expression levels for antioxidant genes (p < 0.01) ( Figure S3F ; Table S1 ), which was paralleled by intracellular accumulation of ROS (8-fold increased) ( Figure 2G BCR-ABL1-and NRAS G12D -driven B-ALL cells were intravenously injected into sublethally irradiated NOD-scid Il2rg À/À (NSG) mice in the presence or absence of Cre (Figures 2J and 2K) . In vivo leukemogenesis was monitored through bioimaging of luciferase-labeled ALL cells ( Figure 2L ). In line with in vitro results, recipient mice injected with Ppp2r1a fl/fl B-ALL cells showed reduced leukemia burden upon deletion of Ppp2r1a and significantly prolonged overall survival in both BCR-ABL1-and NRAS G12D -driven B-ALL models ( Figures 2J and 2K ). To determine whether mice in the Ppp2r1a fl/fl + Cre group succumbed to leukemia because B-ALL can develop in the absence of PP2A (B-ALL with deleted Ppp2r1a alleles) or because some B-ALL clones escaped Cre-mediated deletion (B-ALL retaining Ppp2r1a alleles), we studied the genotype of B-ALL cells that were isolated from enlarged spleens when the mice were euthanized ( Figure 2M ). Genomic and protein expression studies revealed that in all 7 cases, B-ALL developed from Ppp2r1a fl/fl clones that evaded Cre-mediated deletion and expressed normal levels of PP2A. Given that <0.1% of Cre transduced cells escape deletion, these findings demonstrate the strong selective pressure in favor of B-ALL clones that retained Ppp2r1a fl/fl alleles.
PP2A
Restricts Glycolytic Activity In B-Lymphoid, but Not Myeloid, Leukemia Cells AMP-activated protein kinase (AMPK) is negatively regulated by PP2A (Wu et al., 2007) and the active phospho-Ampka-T 172 was identified among the upregulated phosphoproteins upon Ppp2r1a-deletion ( Figure S2A ). We recently found that AMPK-activation in B-ALL cells promotes glycolysis , suggesting that PP2A negatively regulates glycolysis in B cells. Here, we showed that inducible deletion of Ppp2r1a amplified mTORC1 signaling ( Figure S3A ), which was previously shown to stimulate glycolysis as a result of PI3K signaling (Dü vel et al., 2010) . For this reason, we studied the impact of Ppp2r1a-deletion on glucose and energy metabolism in B cell and myeloid lineage leukemias. Inducible ablation of Ppp2r1a in B cells substantially increased glucose consumption, ATP levels, and lactate production (by 3-fold) ( Figure S4A ). Seahorse metabolic analysis revealed that Ppp2r1a-deletion increased glycolytic activity in B-lymphoid 6 mice in each group) followed by 7 days of tamoxifen treatment via oral gavage to induce deletion in vivo (K). In (J) and (K), Kaplan-Meier estimates were used to plot the survival probabilities for mice that were transplanted with Cre-and EV-transduced cells. Log-rank test was used to assess statistical significance. In experiment (J), mice that showed signs of illness from leukemia were sacrificed to collect splenic B-ALL cells. GFP + cells from recipient mice were used for PCR and western blot to determine Ppp2r1a genotype and PP2A expression, respectively (M). Except survival analyses, other experimental data are shown as mean ± SD and representative of at least three independent experiments. See also Figures S2 and S3 and Table S1 . but not myeloid leukemia cells ( Figures 3A and 3B ). Mitochondrial respiration remained unchanged after Ppp2r1a-deletion in both B-lymphoid and myeloid leukemia cells (Figures S4B and S4C) . While glycolysis primarily generates metabolic intermediates and ATP, the pentose phosphatase pathway (PPP) has a critical antioxidant function to generate reducing equivalents, in the form of reduced nicotinamide adenine dinucleotide phosphate (NADPH) (Cairns et al., 2011) . NADPH represents a critical product of the PPP and has important reducing potential to maintain redox balance (Patra and Hay, 2014) . For instance, NADPH can reduce glutathione disulfide (GSSG) to the sulfhydryl form glutathione (GSH), which can salvage oxidative stress (Cairns et al., 2011) . In addition, the PPP is critical for DNA replication in proliferating leukemia cells and generates ribose 5-phosphate (R5P), used in the de novo synthesis of ribonucleotides and later nucleic acids.
PP2A Is Required to Redirect Glucose Carbon Utilization toward the Pentose Phosphate Pathway in B Cells
We examined how loss of PP2A activity affected glucose utilization via glycolysis relative to PPP in B-ALL cells. To trace the activity of glycolysis relative to the PPP pathway upon Ppp2r1a-deletion, we performed mass spectrometry-based metabolite profiling and carbon fate analyses based on 13 C isotopic labels. Carbon fate tracing showing the M1 and M2 isotopomer distribution of lactate derived from [1,2-13 C] glucose was used to distinguish 13 C atoms directly passing through the glycolytic pathway (M2) from 13 C atoms passing through the oxidative arm of the PPP and cycled back to glycolysis (M1). Interestingly, Ppp2r1a-deletion significantly reduced overall carbon utilization through the PPP in B-lymphoid cells while the distribution of M1 (PPP) and M2 (glycolysis) 13 C atoms remained unchanged when Ppp2r1a was deleted in B / Myeloid reprogrammed cells (Figure 3F ; inducible expression of Cebpa). A detailed analysis of individual glycolysis (M2) and PPP (M1) metabolites revealed that Ppp2r1a-deletion in B-lymphoid cells strongly increased labeling of 13 C atoms in multiple glycolytic intermediates (in particular F-1,6-BP) while carbon labeling was consistently reduced for all PPP metabolites studied ( Figure 3C ). Conversely, for B / myeloid reprogrammed cells, inducible deletion of Ppp2r1a had only minor effects and caused modest stimulation of 13 C atoms through both glycolytic (M2) and PPP (M1) intermediates ( Figure 3D ).
PP2A Regulates Glucose Carbon Utilization in B Cells at the Level of Pfkfb2
The relative contribution of glycolysis and PPP flux is controlled by the bifunctional 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase 2 (Pfkfb2) kinase or phosphatase activity (Ros and Schulze, 2013) . Importantly, Ppp2r1a-deletion in B cells, but not myeloid cells, increased phosphorylation of Pfkfb2 at S-483 ( Figure 3E ), which promotes Pfkfb2 kinase (6-phosphofructo-2-kinase [PFK-2]) at the expense of its phosphatase activity (Pozuelo Rubio et al., 2003) . The consequence of enhanced PFK-2 activity is allosteric activation of the rate-limiting enzyme PFK-1 that catalyzes the conversion of fructose-6-phosphate (F6P) to fructose-1,6-bisphosphate (F-1,6-BP) and thereby promotes glycolysis at the expense of the PPP. While F6P can still be utilized in the PPP via G6P as substrate for G6PD, F-1,6-BP is committed to the glycolysis pathway and gives rise to lactate. These findings suggest that PP2A regulates the phosphorylation status of Pfkfb2-S 483 and, thereby, a critical metabolic switch between glycolysis and PPP. Indeed, massively increased S-483 phosphorylation of Pfkfb2 following Ppp2r1a deletion (Figure 3E) , redirects glucose carbon flux from the PPP to glycolysis pathway (Ros and Schulze, 2013) . Functional consequences of this switch in B cells include increased utilization of glycolysis at the expense of the PPP ( Figure 3F ), >20-fold increased conversion of F6P to F-1,6-BP ( Figure 3G ), reduced NADPH/NADP ratios ( Figure 3H ). Consistent with diminished NADPH/NADP ratios, inducible deletion of Ppp2r1a substantially decreased GSH/ GSSG ratios, indicating exhaustion of reductive reserves in B cells upon loss of PP2A function ( Figure 3I ). Interestingly, none of these changes occurred in myeloid cells. While patient-derived B cell leukemia and lymphoma cells (B-ALL, DLBCL and MCL) express PP2A protein at high levels, protein levels for PP2A subunit C are much lower in myeloid leukemia samples (CML) (Tables S2-S4) and virtually undetectable for PP2A subunit A ( Figure 3J ). PP2A expression levels in B cell and myeloid leukemia match the phosphorylation status of Pfkfb2-S 483 ( Figure 3E ), which provides an (J) Western blot to compare PP2A and G6PD expression in patient-derived B-ALL (n = 4; MXP2, LAX2, PDX2, and BLQ5), mantle cell lymphoma (MCL; n = 3; BOS4, BOS5, and BOS6), diffuse large B cell lymphoma (DLBCL; n = 2; BOS10, and BOS12), and chronic myeloid leukemia (n = 10; Table S4 ) samples. Data are shown as mean ± SD and representative of at least three independent experiments. See also Figure S4 and Tables S2 and S3. explanation for the strikingly different outcome of PP2A-deletion in B cell-and myeloid leukemia cells. Tigar rescued B-ALL cells from cell death and induced a strong survival advantage ( Figures 4C and 4D ). Inducible deletion of Ppp2r1a in B cell ALL substantially decreased NADPH/NADP ratios (Figure 4E) . As expected, normal NADPH/ NADP ratios were restored by reconstitution of Sub A expression using a retroviral overexpression vector (compared to empty vector [EV]; Figure 4E ). Overexpression of Tigar in B-ALL cells with intact PP2A-function induced a slight increase of NADPH/NADP ratios. Inducible deletion of Ppp2r1a substantially decreased NADPH/NADP ratios, which was fully restored by Tigar overexpression, comparable to restoration of Ppp2r1a itself ( Figure 4F ). The important role of TIGAR in the diverting glucose carbon flux from glycolysis to the PPP (Bensaad et al., 2006; Cheung et al., 2013) , and the ability of Tigar overexpression to fully substitute for PP2A (Figure 4 ) support the concept that PP2A serves an essential role in the survival of B cells by balancing carbon utilization of glycolysis versus PPP. Given the complexity of redox regulation, it is likely that factors other than PPP also contribute to loss of NADPH upon Ppp2r1a deletion of in B cells. (legend continued on next page) exception of B-ALL (Shojaee et al., 2016) . Likewise, we found that mutations and deletions of PPP2R1A occur frequently throughout multiple cancer types of cancer but were not detected in B-ALL and B cell lymphoma. In solid tumors across 16 types of cancer (23,009 samples studied), we found genetic lesions of PPP2R1A on average in 3% of cases studied (range, 0.5%-14%). On the other hand, genetic lesions of PPP2R1A were also found in myeloid leukemia (187 samples studied) but not in B cell leukemia and lymphoma (323 samples studied) (Figure S5A ). These genetic findings show that malignant clones in B cell tumors are-unlike other types of cancer-not positively selected for loss of PP2A function. On the premise that PP2A regulates a central metabolic switch between glycolysis and PPP, we studied expression levels of glycolysis and PPP-related enzymes in B cell compared to myeloid malignancies ( Figures S4D and S5B ). Studying 807 B-lymphoid leukemia patient samples and 355 myeloid samples, we found substantially higher mRNA levels of glycolytic PFK-1 enzymes in B-lymphoid compared to myeloid samples (PFKL, p < 0.0001; PFKM, p = 0.0091; PFKP, p < 0.0001) ( Figure  S4D ). Interestingly, while we did not detect mutations in PP2A subunits, we found 19 somatic mutations in PFK-1 enzymes in a panel of 56 B-ALL and B cell lymphoma cell lines (Table S5) . Conversely, mRNA levels of PPP enzymes were substantially downregulated in B-lymphoid compared to myeloid samples (G6PD, PGD, RPIA, RPE, TKT, and TALDO1, p < 0.0001 for each gene) ( Figure S4D ). Glucose-6-phosphate dehydrogenase (G6PD) and 6-phosphogluconate dehydrogenase (PGD) catalyze the rate-limiting steps of PPP and promote PPP relative to glycolysis (Hitosugi et al., 2012; Lin et al., 2015) . Compared to normal myeloid progenitor cells (n = 32) and myeloid leukemia (n = 156), mRNA levels of PPP2R1A, PPP2CA, and G6PD are low in normal (n = 24) and malignant (n = 455) B cell populations ( Figure S5B ).
B-Lymphoid Transcription Factors Repress G6PD and PPP Activity
Cebpa-mediated reprogramming of B cells into the myeloid lineage gradually increased mRNA and protein levels of G6PD and PGD ( Figures 5A and 5B ). Chromatin immunoprecipitation sequencing (ChIP-seq) data from human B cells showed enriched binding of these B-lymphoid transcription factors on G6PD promoters, which was confirmed by single-locus quantitative ChIP ( Figures 5C and 5D ). The B-lymphoid transcription factors PAX5 and IKZF1 negatively regulate glucose uptake and are frequently deleted in B-lineage ALL . Interestingly, restoration of PAX5 expression in a Pax5-deficient mouse model of B-lineage ALL (Liu et al., 2014) significantly repressed G6pdx and G6pd2 expression levels ( Figure 5E ). Likewise, restoration of PAX5 and IKZF1 in PAX5-and IKZF1-deficient patient-derived B-lineage ALL xenografts reduced G6PD to levels at or below the detection limit (Figure 5F ). In some cases, genetic lesions of PAX5 and IKZF1 result in expression of dominant-negative (DN) transcription factors (PAX5-ETV6; intragenic deletion of IKZF1 zinc fingers). Overexpression of DN-PAX5 and DN-IKZF1 in patient-derived B-lineage ALL xenografts expressing functional PAX5 and IKZF1 induced strong upregulation of G6PD ( Figure 5F ) demonstrating that functional G6PD deficiency in B cells is the result of B-cell-specific transcriptional repression. Interestingly, higher than median expression levels of G6PD are associated with poor clinical outcome and shorter overall survival in all four clinical trials that we studied for patients with B cell lymphomas but not in patients with acute myeloid leukemia (Figures 5G and 5H) .
Studying PP2A and G6PD protein levels in patient-derived xenografts of B cell malignancies, we confirmed that B cell tumors generally express high levels of PP2A subunit A and C and low levels of the PPP rate-limiting enzyme G6PD compared to patient-derived myeloid leukemia samples ( Figure 3J ). These findings suggest that B cell intrinsic repression of the rate-limiting PPP enzyme G6PD may serve as a gatekeeper function to safeguard against malignant transformation, while higher expression levels of G6PD are associated with a more aggressive course of disease in B cell malignancies. To test whether G6PD was sufficient to rescue inducible ablation of Ppp2r1a in B cell ALL cells, we overexpressed murine G6pdx and human G6PD and verified increased expression levels by western blot ( Figure S6A ). Unlike TIGAR, which redirects carbon glucose flux from glycolysis to the PPP, the PPP key enzyme G6PD (murine G6pdx and human G6PD) was not sufficient to rescue B-ALL cell death upon inducible deletion of Ppp2r1a (Figures S6B and S6C ). This is a central difference from TIGAR (Figure 4) , which unlike G6PD has no direct function in the PPP but controls supply of the PPP with glucose carbon flux (Bensaad et al., 2006) .
Transcription Factors that Determine B Cell Identity
Regulate PPP Activity and Dependency on PP2A We tested the hypothesis that B-cell-specific transcription factors are responsible for low PPP activity in B cells, hence PP2A as a B-cell-specific vulnerability. To this end, we replaced the four stem cell factors (Oct4, Sox2, Nanog, and Myc) those were previously used to generate induced pluripotent stem cells (iPSCs) (Takahashi and Yamanaka 2006) with the four B cell transcription factors (Pax5, Ikaros, Ebf1, and Tcf3). Inducible activation of this polycistronic vector in human embryonic kidney cells resulted in expression of all four B-lymphoid transcription factors and substantial reduction of NADPH/NADP ratios ( Figures 6A and 6B ). In addition, doxycycline-inducible expression was sufficient to reprogram (F) Except clinical outcome studies, experimental data are shown as mean ± SD and representative of at least three independent experiments. See also Figure S5 and Table S5 .
murine myeloid leukemia cells into B cells (Figures 6C and  6D ). Myeloid / B cell reprogramming downregulated G6PD and upregulated PP2A ( Figure 6E ) and hence recapitulated metabolic characteristics of B cells ( Figure 3J ). In a third approach, we studied small cell lung cancer cells (SCLC). further ( Figure 6G ). These effects depend on PAX5 and likely other B-lymphoid transcription factors and can occur in non-B cells (e.g., kidney, myeloid, and SLCL cells) when PAX5 is aberrantly expressed. While not the focus of this study, these findings suggest a previously unexplored rationale for specific targeting of PP2A and G6PD in SCLC cells.
Target Validation of PP2A in Human B Cell Malignancies
In proof-of-concept experiments, we have tested the PP2A small molecule inhibitor LB-100 (4-methylpiperazin-1-yl-7-oxabicyclo-heptane-2-carboxylic acid) and the G6PD-inhibitor by 6-aminonicotinamide (6-AN) ( Figure S7A ) in B cell leukemia and lymphoma samples. LB-100, the first-in-class PP2A inhibitor studied here is currently in two clinical trials (NCI designated NCT03027388 and NCT01837667). A phase-1 safety study with 7 dose-escalations did not note relevant toxicity (Chung et al., 2017) . LB-100 is a water-soluble small molecule inhibitor of PP2A (IC 50 0.9 mmol/L) and was initially designed to sensitize solid tumors to chemotherapy (Lu et al., 2009) .
To document feasibility, we injected C57B/6J mice with LB-100 (1.5 mg/kg) five times over the course of 9 days and monitored PP2A inhibition in normal T cell subsets ( Figures  S7C-S7E ) and myeloid subsets, which showed minimal impact. Interestingly, a recent study showed that proarthritogenic T cells in rheumatoid arthritis are dependent on PPPmediated antioxidant protection (Yang et al., 2016) , suggesting that targeting of PP2A alone or in combination with G6PD may be useful for these patients. Here, we used LB-100 to study pharmacological PP2A ablation in the context of Pax5 and Ebf1 haploinsufficiency (hemizygous Pax5 and Ebf1 deletions). To this end, Pax5
Ebf1
+/À B-ALL cells and wild-type control B-ALL cells were treated with LB-100 at the concentrations indicated, and cell viability was measured. Interestingly, partial or complete loss of B-cell-specific transcription factors (e.g., Pax5 and Ebf1) relieved dependency on PP2A and resulted in reduced sensitivity to LB-100 in B cells ( Figure 6H ).
CRISPR/Cas9-Mediated Genetic Ablation of PPP2R1A in Patient-Derived B Cell ALL We transduced patient-derived Ph + ALL cells with inducible Cas9
and three different guide-RNAs directed against PPP2R1A and a non-targeting guide ( Figure 7A ; Table S6 ). Western blot analysis revealed that deletion of PPP2R1A was achieved at varying levels. The extent of PPP2R1A deletion correlated with loss of the catalytic PP2A subunit C and phosphorylation of H2AX (S139) ( Figure 7A ). Compared to patient-derived Ph + ALL cells carrying Cas9 and a non-targeting guide RNA, three different guideRNAs directed against PPP2R1A induced depletion of B-ALL cells from cell culture ( Figures 7B and S7B ), confirming dependency of patient-derived B-ALL cells on PP2A function.
Feasibility and Efficacy of Pharmacological PP2A Inhibition in B Cell Malignancies
Studying biochemical activity of LB-100 in patient-derived Ph + ALL cells, we found that near-complete loss of PP2A activity at 5 mmol/L ( Figure 7C ) was paralleled by strong activation of AKT-mTOR signaling and H2AX-phosphorylation ( Figure 7D ), which is consistent with increased ROS-levels in patient-derived Ph + ALL cells ( Figure 7E ). Consistent with lineage-specific effects of Ppp2r1a deletion ( Figure 1I ), LB-100 selectively induced cell death in B cell leukemia and lymphoma PDX but not myeloid leukemia cells (CML, AML) ( Figures 7F-7H ). Owing to B-lymphoid transcriptional repression of G6PD and other central PPP enzymes ( Figures 5A-5F ), B cells are uniquely vulnerable to PPP inhibition. In agreement with these results, we found that pharmacological inhibition of G6PD by 6-AN further exacerbated B cellintrinsic G6PD deficiency and induced cell death in B cell leukemia and lymphoma but not myeloid leukemia cells (Figure 7I) . Interestingly, combination studies of LB-100 and 6-AN revealed that direct (6-AN via G6PD) and indirect (LB-100 via PP2A) . Intraperitoneal injection of LB-100 (1.5 mg/kg), 6-AN (1 mg/kg), or combination (1.5 mg/kg LB-100 + 1 mg/kg 6-AN) started 7 days after cell injection at indicated time points. Kaplan-Meier survival curves are shown. Log-rank test was used to assess statistical significance of each treated group compared to vehicle group. Except for Kaplan-Meier survival analyses, other experimental data are shown as mean ± SD and representative of at least three independent experiments. See also Figure S7 and Tables S6 and S7. inhibition of PPP strongly synergized in patient-derived Ph + ALL, mantle cell lymphoma, and DLBCL cells (Figures 7J-7L ; Table  S7 ). To test this therapeutic concept in a preclinical transplant experiment, we injected patient-derived DLBCL cells (Table S3) carrying concurrent MYC and BCL2 gene rearrangements into NSG mice and treated the mice with LB-100 (1.5 mg/kg), 6-AN (1 mg/kg), or a combination of both via intraperitoneal (i.p.) injections. The Kaplan-Meier analysis on day 50 showed a significant difference in survival for the LB-100 (p = 0.0005) or LB-100 +6AN (p = 0.0002) arms compared to vehicle controls ( Figure 7M ; logrank test). In summary, we propose that targeting of PP2A in B cell malignancies is immediately translatable given the evidence supporting safety of LB-100. Our studies provide a strong rationale for agents that will target PP2A, TIGAR or G6PD as lineage-specific and previously unrecognized vulnerabilities in B cell malignancies (B-ALL and B cell lymphoma).
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EXPERIMENTAL MODEL AND SUBJECT DETAILS

Cell lines
Leukemia cell lines were maintained in Roswell Park Memorial Institute (RPMI) 1640 medium (GIBCO) with GlutaMAX supplemented with 10%-20% fetal bovine serum (FBS), 100 IU/mL penicillin and 100 mg/mL streptomycin (GIBCO). Small cell lung cancer cell lines provided by Dr. Ravi Salgia, were cultured in the same condition as for leukemia cell lines. All cell lines were cultured at 37 C in a humidified incubator with 5% CO 2 . All cell lines were tested to be mycoplasma free by MycoAlert PLUS kit (LONZA). cultured on OP9 stroma cells in Alpha Minimum Essential Medium (MEMa; GIBCO) with GlutaMAX supplemented with 20% FBS, 1mM sodium pyruvate, 100 IU/mL penicillin and 100 mg/mL streptomycin at 37 C in a humidified incubator with 5% CO 2 . Before experimental usage, all the human xenografts were tested to be mycoplasma free (MycoAlert PLUS, LONZA).
Patient-derived B-ALL and B cell lymphoma samples
Murine primary and leukemia cells
Bone marrow and splenic cells were harvested from mice between 6-8 weeks of age without signs of inflammation. After filtration through a 70 mm cell strainer, cells were supplied to lysis buffer based erythrocytes depletion (RBC Lysis Buffer, BioLegend). Resuspended cells were then used for further experiments. Bone marrow cells were cultured in Iscove's Modified Dulbecco's Medium (IMDM; GIBCO) with GlutaMAX supplemented with 20% FBS, 100 IU/mL penicillin, 100 mg/mL streptomycin and 50 mmol/L b-mercaptoethanol (GIBCO). Bone marrow cells, for IL-7-dependent pre-B cell culture were cultured in full IMDM supplemented with 10 ng/mL recombinant mouse IL-7 (PeproTech). To generated murine B-lineage Ph + ALL cell, retroviral transduction of BCR-ABL1 was performed to cultured pre-B cells. After transformation with BCR-ABL1, ALL cells were cultured in IL-7-withdrawed IMDM. NRAS G12D B-ALL cells were selected with puromycin (GIBCO) and were maintained with IL-7 supplemented IMDM. Murine B-ALL cells were cultured no longer than 2 months to avoid accumulation of additional genomic mutations. Murine BCR-ABL1 B-ALL cells used in 1,2-2 13 C D-Glucose tracing and metabolites profiling experiments, were cultured in glucose-free DMEM with 20% dialyzed FBS, 100 IU/mL penicillin, 100 mg/mL streptomycin and 50 mmol/l b-mercaptoethanol (GIBCO). The same medium with 25 mmol/l 1,2-2 13 C D-Glucose (Cambridge Isotope Laboratories) was used labeling during a 24 hr interval. For myeloid leukemia (CML-like) cells, the myeloid-specific protocol described previously was used. In brief, murine bone marrow cells were cultured in IMDM containing 10 ng/mL recombinant mouse IL-3, 25 ng/mL recombinant mouse IL-6 and 50 ng/mL recombinant mouse stem cell factor (SCF; PeproTech). After BCR-ABL1 mediated transformation, murine CML-like cells were cultured in IMDM without additive cytokines. Lineage-specific characterization of BCR-ABL1-transformed Ph + ALL and CML-like cells was performed by flow cytometry (LSRFortessa, BD Biosciences). Mature splenic B cells were cultured in IMDM with 20% FBS, 100 IU/mL penicillin, 100 mg/mL streptomycin and 50 mmol/L b-mercaptoethanol (GIBCO), supplemented with 10 ng/mL mouse IL-4 (Pepro Tech), 100 ng/mL human BAFF (Cell Guidance Systems) and 1 mg/mL mouse CD40L (Cell Guidance Systems). After 2 days in cell culture, more than 90% of the cells were CD19 + B cells and were used for further experiments. 
Ppp2r1a
fl/fl mice were backcrossed to C57BL/6 background for more than 8 generations. Vav-tTAxTet off -shPax5 mice were obtained from Dr. Ross A. Dickins. For animals bred in house, littermates of the same sex were randomized to experimental groups. All mouse breeding and experiments were subject to institutional approval by the Beckman Research Institute Animal Care and Use Committee.
METHOD DETAILS
Flow cytometry Cells were washed in PBS and subjected to Fc receptor blocking (TruStain, Biolegend) for 10 min at room temperature. 10 6 cells per mL were used to perform staining with antibodies listed for 15-30 min at 4 C. After washing with PBS, cells were suspended in PBS with propidium iodide (PI, 0.2 mg/mL) or DAPI (0.75 mg/mL) to exclude dead cells. For cell-cycle analysis, the Click-iT EdU Flow Cytometry Assay Kit (Life Technologies) was used according to the manufacturer's instructions. To measure intracellular ROS levels, cells were incubated for 7 min with 1 mmol/L 5-(and-6)-chloromethyl-2 0 ,7'-dichlorodihydrofluorescein diacetate, acetyl ester (CM-H 2 DCFDA, Life Technologies) at 37 C. After washing with PBS, the cells were incubated for additional 15 min at 37 C in PBS. Fluorescence signals from oxidated CM-H 2 DCFDA in viable cells were measured by flow cytometry. All flow cytometry assays were performed on a LSRFortessa (BD Biosciences). All the fluorescence-activated cell sorting procedures were performed on a FACSAria II (BD Biosciences). Flow cytometry data were exported and analyzed with FlowJo (FlowJo, LLC).
Western blotting PBS washed cells were lysed in CelLytic buffer (Sigma-Aldrich) supplemented with 1% protease inhibitor cocktail (Fisher Scientific). 20 mg of protein lysates per sample were separated on Criterion TGX (Bio-Rad) 4%-20% Tris-Glycine eXtended gradient gels and transferred on nitrocellulose membranes (Bio-Rad). The Western Breeze Immunodetection System (Life Technologies) was used for signal development, and chemiluminescent signal was detected by X-ray film exposure. Primary antibodies used for western blotting are listed below.
PP2A phosphatase activity measurement 2 3 10 7 leukemia cells were used for measuring PP2A activity following manufacturer's protocol. PP2A Immunoprecipitation Phosphatase Assay Kit (17-313, Millipore) was used to perform this assay. 
Retroviral and lentiviral transduction
Constructs used for retroviral or lentiviral transduction are listed in the key resources Table. Virus production was performed with HEK293FT cells (Life Technologies) using Lipofectamine 2000 (Life Technologies). Cells were co-transfected with the plasmid of interest, pHIT60 (gag-pol) and pHIT123 (ecotropic env; kindly provided by Donald B Kohn, UCLA). HEK293FT cells were cultured in high glucose Dulbecco's modified Eagle's medium (DMEM, GIBCO) with GlutaMAX supplemented with 10% FBS, 100 IU/mL penicillin, 100 mg/mL streptomycin, 25 mM HEPES, 1 mM sodium pyruvate and 0.1 mM non-essential amino acids (GIBCO). 16h after liposomal transfection, cell culture medium was replaced by full grow media, supplemented with 10 mM sodium butyrate. After 8 hr, cell culture medium was replaced with full grow media. 24 hr later, the virus-containing supernatant was collected and filtered through 0.45 mm filters. Cell transduction was performed with RetroNectin (TAKARA) according to manufactures protocol. Lentiviral particles were produced via co-transfection of plasmid of interest with pCD/NL-BH*DDD and EM140 like the retroviral particle production. Antibiotic selection was performed on transduced cells according to the specific antibiotic resistance carried by the respective construct.
Colony forming assay for murine ALL cells 10,000 B-ALL cells were resuspended in 1 mL murine MethoCult medium (M3231 or M3630, STEMCELL Technologies) and cultured in 35 mm dishes at 37 C in a humidified incubator with 5% CO 2 . Colony numbers were counted after 7-14 days using an automated colony counter.
NADPH/NADP ratio measurement 2 3 10 7 cells were harvested and subjected to measure NADPH/NADP ratio by NADP/NADPH Assay Kit (ab65349, Abcam). NADPH/ NADP ratios relative to control cells were calculated in each experiment.
Affymetrix GeneChip expression analysis
Total RNA was isolated using the NucleoSpin RNA kit (MACHEREY-NAGEL). RNA quality was determined with the Agilent Bioanalyzer (Agilent Technologies). Biotinylated cRNA was generated and fragmented based on the Affymetrix protocol and hybridized to mouse Gene 1.0 ST (Affymetrix). After scanning (GeneChip Scanner 3000 7G; Affymetrix) of the arrays, the CEL files generated were analyzed using BRB Array Tool (https://linus.nci.nih.gov/BRB-ArrayTools.html) and processed using the RMA algorithm (robust multi-array average) for normalization and summarization. Gene expression ratios were processed and visualized as a heatmap utilizing Gene Cluster and Java Treeview. Gene Set Enrichment Analysis (GSEA) was performed using list in Table S1 with GSEA software. Raw data are available via GEO accession number GSE83742.
In vivo leukemia and lymphoma cell transplantation Ppp2r1a fl/fl BCR-ABL1 B-ALL cells were transduced with retrovirus to overexpress firefly luciferase, selected with puromycin, and then transduced with Cre-IRES-GFP or GFP empty vector. 2 days after transduction, GFP + cells were sorted by FACSAria II (BD Biosciences) and genotyping was performed to verify Cre mediated deletion. 1 3 10 6 viable cells were intravenously injected into sublethally irradiated (2 Gy) NSG mice (6-8 weeks old females). Comparable viability and luciferase activity of Cre-IRES-GFP and GFP transduced cells were confirmed by flow-cytometry and D-Luciferin (Gold Bio) induced bioluminescence signal. Leukemia progression in mice was monitored at the times indicated using an in vivo IVIS Spectrum bioluminescence/optical imaging system (PerkinElmer Inc). 2.5 mg D-Luciferin (dissolved in PBS) per mouse was injected intraperitoneally 15 min before measuring. General anesthesia was induced with 5% isoflurane and continued during the procedure with 2% isoflurane introduced through a nose cone. Ppp2r1a fl/fl Nras G12D ALL cells were transduced with Cre-ER T2 -IRES-GFP or ER T2 -IRES-GFP empty vector. 2 days after transduction, GFP + cells were sorted by FACSAria II (BD Biosciences). 3 3 10 6 viable cells after 24 hours' 4-OHT treatment were intravenously injected into sublethally irradiated (2 Gy) NSG mouse (6-8 weeks female). After transplantation, 5 mg/mouse/day Tamoxifen (Sigma-Aldrich) was administrated to recipient mice with Nras G12D ALL cells for 7 days through oral gavage. 3 3 10 6 viable patient-derived diffuse large B cell lymphoma cells (BOS12 ;   Table S3 ) were intravenously injected into sublethally irradiated (2 Gy) NSG mouse (6-8 weeks female). Treatment of vehicle, LB-100 (1.5 mg/kg; dissolved in 0.1 mol/L monosodium glutamate PH 10.5 and diluted in PBS before use), 6-AN (1 mg/kg; dissoveld in 10 % 1-methyl-2-pyrrolidinone + 90% polyethylene glycol 300 and diluted in PBS before use) or combination (1.5 mg/kg LB-100 + 1 mg/kg 6-AN) started 7 days after transplantation by intraperitoneal injection. Mice were euthanized when they reached the criteria of terminal sickness caused by leukemia. Bone marrow and spleen cells were collected for CRISPR-Cas9 plasmid set including all gRNAs for target genes were obtained from transOMIC technologies. The gRNA sequences that were used are listed in Table S6 .
Cell viability assays 4 3 10 4 human or mouse leukemia cells were seeded in a volume of 50 mL in complete growth medium on 96-well plates (Eppendorf).
Compounds were added at the indicated concentrations in a total volume of 100 mL per well. After culturing for 3 days, cells were subjected to CCK-8 (Dojindo) or CellTiter-Glo Luminescent Cell Viability Assay (Promega). Medium without cells was used as blank.
Relative viability was calculated using baseline values of untreated cells as a reference. For LB-100 (S7537, Selleck Chemicals) and 6-AN (A68203, Sigma-Aldrich) single treatment shown in Figures 7H and 7I , Ph + ALL xenografts including LAX2, MXP2, PDX2 and BLQ5 (n = 4) and myeloid leukemia including KYO-1, EM-2, JURL-MK1 and MV4-11 (n = 4) were used.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis was performed using GraphPad Prism 7 (GraphPad Software Inc.) and were shown as mean ± SD as indicated. Unpaired 2-tailed Student's t test was used to evaluate difference between two groups and P values were plotted (p < 0.05 was considered statistically significant). For in vivo transplantation experiments, the minimal number of mice in each group was calculated through use of the 'cpower' function in the R/Hmisc package. Kaplan-Meier survival analysis was used to estimate OS with GraphPad Prism 7 and log-rank test was used to compare the difference between two groups. For patient overall survival analysis, patients in each dataset were segregated into 2 groups based on 25% highest or 25% lowest mRNA levels of the gene of interest. The datasets used include mantle cell lymphomas (GEO: GSE10793, n = 71 and https://llmpp.nih.gov/MCL, n = 92), diffuse large B cell lymphoma (DLBCL; GEO: GSE10846, n = 414), B cell lineage CLL (GEO: GSE22762, n = 107) and acute myeloid leukemia (http://www. cbioportal.org/study?id=laml_tcga_pub#clinical; n = 200). Log-rank test was used to compare survival differences between patient groups. R package ''survival'' Version 2.35-8 was used for the survival analysis and Cox proportional hazards regression model in R package for the multivariate analysis (R Development Core Team, 2008) . To determine synergism effect of LB-100 and 6-AN in B-ALL and B cell lymphoma cells, combination index (CI) values were calculated using the CompuSyn software to determine interaction (synergistic, CI < 1; additive, CI = 1; or antagonistic, CI > 1).
DATA AND SOFTWARE AVAILABILITY
The accession number for the gene expression arrays reported in this paper is GEO: GSE83742. Table   S6 ) depicted in the schematic (A). IL7-dependent B cell precursors propagated from Ppp2r1a fl/fl mice were transformed with BCR-ABL1 or NRAS
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